Brief: Cassava Sciences Q2 Basic EPS USD 0.13
08/08/2024 13:00
Aug 08 (Reuters) - Cassava Sciences Q2 operating expenses USD 61.402 million. * Q2 net income USD 6.155 million * Q2 operating income USD -61.402 million
Recent news on Filana Therapeutics
See all newsCassava Sciences says US DOJ has closed investigation into company (updated)
Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences says US DOJ has closed investigation into company
Brief: Cassava Announces Agreement To Settle Securities Class Action Litigation
Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing